Intracellular signalling involved in modulating human endothelial barrier function

被引:115
作者
van Hinsbergh, VWM [1 ]
Amerongen, GPV
机构
[1] Vrije Univ Amsterdam Med Ctr, Inst Cardiovasc Res, Dept Physiol, Amsterdam, Netherlands
[2] TNO, PG, Gaubius Lab, Leiden, Netherlands
关键词
endothelial barrier function; intracellular signalling;
D O I
10.1046/j.1469-7580.2002.00060.x
中图分类号
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号
100101 ;
摘要
The endothelium dynamically regulates the extravasation of hormones, macromolecules and other solutes. In pathological conditions, endothelial hyperpermeability can be induced by vasoactive agents, which induce tiny leakage sites between the cells, and by cytokines, in particular vascular endothelial growth factor, which increase the exchange of plasma proteins by vesicles and intracellular pores. It is generally believed that the interaction of actin and non-muscle myosin in the periphery of the endothelial cell, and the destabilization of endothelial junctions, are required for endothelial hyperpermeability induced by vasoactive agents. Transient short-term hyperpermeability induced by histamine involves Ca2+/calmodulin-dependent activation of the myosin light chain (MLC) kinase. Prolonged elevated permeability induced by thrombin in addition involves activation of the small GTPase RhoA and Rho kinase, which inhibits dephosphorylation of MLC. It also involves the action of other protein kinases. Several mechanisms can increase endothelial barrier function, depending on the tissue affected and the cause of hyperpermeability. They include blockage of specific receptors, and elevation of cyclic AMP by agents such as beta(2)-adrenergic agents. Depending on the vascular bed, nitric oxide and cyclic GMP can counteract or aggravate endothelial hyperpermeability. Finally, inhibitors of RhoA activation and Rho kinase represent a potentially valuable group of agents with endothelial hyperpermeability-reducing properties.
引用
收藏
页码:549 / 560
页数:12
相关论文
共 116 条
  • [31] Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97
  • [32] DVORAK HF, 1995, AM J PATHOL, V146, P1029
  • [33] Induction of endothelial cell chemotaxis by sphingosine phosphate and stabilization of endothelial monolayer barrier function by lysophosphatidic acid, potential mediators of hematopoietic angiogenesis
    English, D
    Kovala, AT
    Welch, Z
    Harvey, KA
    Siddiqui, RA
    Brindley, DN
    Garcia, JGN
    [J]. JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 1999, 8 (06): : 627 - 634
  • [34] Vascular endothelial growth factor induces endothelial fenestrations in vitro
    Esser, S
    Wolburg, K
    Wolburg, H
    Breier, G
    Kurzchalia, T
    Risau, W
    [J]. JOURNAL OF CELL BIOLOGY, 1998, 140 (04) : 947 - 959
  • [35] Thrombin inactivates myosin light chain phosphatase via Rho and its target Rho kinase in human endothelial cells
    Essler, M
    Amano, M
    Kruse, HJ
    Kaibuchi, K
    Weber, PC
    Aepfelbacher, M
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (34) : 21867 - 21874
  • [36] Pathways of macromolecular extravasation across microvascular endothelium in response to VPF VEGF and other vasoactive mediators
    Feng, D
    Nagy, JA
    Pyne, K
    Hammel, I
    Dvorak, HF
    Dvorak, AM
    [J]. MICROCIRCULATION, 1999, 6 (01) : 23 - 44
  • [37] Phosphorylation of adducin by rho-kinase plays a crucial role in cell motility
    Fukata, Y
    Oshiro, N
    Kinoshita, N
    Kawano, Y
    Matsuoka, Y
    Bennett, V
    Matsuura, Y
    Kaibuchi, K
    [J]. JOURNAL OF CELL BIOLOGY, 1999, 145 (02) : 347 - 361
  • [38] Effect of inhaled nitric oxide or inhibition of endogenous nitric oxide formation on hyperoxic lung injury
    Garat, C
    Jayr, C
    Eddahibi, S
    Laffon, M
    Meignan, M
    Adnot, S
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 155 (06) : 1957 - 1964
  • [39] Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement
    Garcia, JGN
    Liu, F
    Verin, AD
    Birukova, A
    Dechert, MA
    Gerthoffer, WT
    Bamburg, JR
    English, D
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (05) : 689 - 701
  • [40] GARCIA JGN, 1995, J INVEST MED, V43, P117